{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:03:00Z","timestamp":1772233380852,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1684\/bdc.2010.1168","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T16:01:59Z","timestamp":1565712119000},"page":"1105-1117","source":"Crossref","is-referenced-by-count":10,"title":["Alternatives th\u00e9rapeutiques \u00e0 la L-asparaginase native dans le traitement de la leuc\u00e9mie aigu\u00eb lymphoblastique de l'adulte"],"prefix":"10.1016","volume":"97","author":[{"given":"X.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cannas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Chelghoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gougounon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2010.1168_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2141.1997.3613175.x","article-title":"Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical research council working party on leukaemia in adults","volume":"99","author":"Durrant","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0010","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.1993.11.10.1990","article-title":"Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy","volume":"11","author":"Fiere","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0015","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0020","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1365-2141.1996.00394.x","article-title":"For the GIMEMA Cooperative Group. The GIMEMA ALL 0183 trial, analysis of 10-year follow-up","volume":"92","author":"Mandelli","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0030","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0035","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0045","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V85.5.1151.bloodjournal8551151","article-title":"The biology and treatment of acute lymphoblastic leukemia in adults","volume":"85","author":"Copelan","year":"1995","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0050","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P","article-title":"Acute lymphoblastic leukemia: A comprehensive review with emphasis on biology and therapy","volume":"76","author":"Cortes","year":"1995","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0060","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","article-title":"Outcome of Phildelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"36","author":"Faderl","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1684\/bdc.2010.1168_bib0070","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","article-title":"A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969","volume":"6","author":"Gaynor","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0075","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1168_bib0080","first-page":"833","article-title":"Strat\u00e9gies th\u00e9rapeutiques actuelles dans les leuc\u00e9mies aigu\u00ebs lymphoblastiques de l'adulte","volume":"90","author":"Thomas","year":"2003","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0085","first-page":"713","article-title":"Leuc\u00e9mie aigu\u00eb lymphoblastique du sujet \u00e2g\u00e9 : pronostic et traitement","volume":"91","author":"Thomas","year":"2004","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1517\/14656560802618746","article-title":"Chemotherapy of acute leukemia in adults","volume":"10","author":"Thomas","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1684\/bdc.2010.1168_bib0095","first-page":"S130","article-title":"Follow-up of the first two successive german multicentre trials for adult ALL (01\/81 and 02\/84)","volume":"7","author":"Hoelzer","year":"1993","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1168_bib0100","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana Farber Cancer Institute ALL Consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0110","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the pediatric-based protocol PETHEMA ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1684\/bdc.2010.1168_bib0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokin"},{"key":"10.1684\/bdc.2010.1168_bib0125","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.98.6.565","article-title":"Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum","volume":"98","author":"Kidd","year":"1953","journal-title":"J Exp Med"},{"key":"10.1684\/bdc.2010.1168_bib0135","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/1911114a0","article-title":"Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects","volume":"191","author":"Broome","year":"1961","journal-title":"Nature"},{"key":"10.1684\/bdc.2010.1168_bib0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0003-9861(64)90032-3","article-title":"Tumor inhibitory effect of L-asparaginase from Escherichia coli","volume":"105","author":"Mashburn","year":"1964","journal-title":"Arch Biochem Biophys"},{"key":"10.1684\/bdc.2010.1168_bib0145","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Children's Cancer Study Group","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1168_bib0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1168_bib0155","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/1097-0142(197810)42:4<1730::AID-CNCR2820420411>3.0.CO;2-K","article-title":"Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia","volume":"42","author":"Sackmann-Muriel","year":"1978","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0160","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1021\/bi00820a013","article-title":"Escherichia coli L-asparaginase. Catalytic activity and subunit nature","volume":"9","author":"Jackson","year":"1970","journal-title":"Biochemistry"},{"issue":"4","key":"10.1684\/bdc.2010.1168_bib0165","first-page":"111","article-title":"L-Asparaginase: discovery and development as a tumor-inhibitory agent","volume":"65","author":"Broome","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1684\/bdc.2010.1168_bib0170","first-page":"929","article-title":"Evaluation of L-asparagine metabolism in animals and man","volume":"30","author":"Cooney","year":"1970","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1168_bib0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1684\/bdc.2010.1168_bib0180","first-page":"2297","article-title":"Biochemical and pharmacological studies with L-asparaginase in man","volume":"30","author":"Ohnuma","year":"1970","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1168_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","article-title":"Toxicity of Escherichia coli L-asparaginase in man","volume":"25","author":"Oettgen","year":"1970","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","article-title":"Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia","volume":"37","author":"Killander","year":"1976","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mpo.2950030410","article-title":"Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia","volume":"3","author":"Jones","year":"1977","journal-title":"Med Pediatr Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2353\/ajpath.2006.051238","article-title":"L-asparaginase-induced antithrombin type I deficiency","volume":"169","author":"Hernandez-Espinoza","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1684\/bdc.2010.1168_bib0210","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190410001693588","article-title":"Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin","volume":"45","author":"Elliott","year":"2004","journal-title":"Leuk Lymph"},{"key":"10.1684\/bdc.2010.1168_bib0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(86)92304-4","article-title":"Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase","volume":"1","author":"Leonard","year":"1986","journal-title":"Lancet"},{"key":"10.1684\/bdc.2010.1168_bib0220","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/1097-0142(19800415)45:8<2017::AID-CNCR2820450806>3.0.CO;2-C","article-title":"Factors related to length of complete remission in adult acute leukemia","volume":"45","author":"Keating","year":"1980","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0225","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","article-title":"L-asparaginase resistance in human leukemia \u2013 asparagine synthetase","volume":"18","author":"Haskell","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"10.1684\/bdc.2010.1168_bib0230","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.1999.17.5.1568","article-title":"Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia","volume":"17","author":"Woo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.arcped.2004.07.020","article-title":"Pancr\u00e9atites aigu\u00ebs s\u00e9v\u00e8res \u00e0 l'asparaginase chez l'enfant : \u00e9tude r\u00e9trospective multicentrique","volume":"12","author":"Laugel","year":"2005","journal-title":"Arch Pediatr"},{"key":"10.1684\/bdc.2010.1168_bib0240","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagines levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0245","first-page":"55","article-title":"Monitoring the asparaginase activity and asparagine levels in children with acute lymphoblastic leukaemia treated with different asparaginase preparations","volume":"77","author":"Konecna","year":"2004","journal-title":"Scripta Medica"},{"key":"10.1684\/bdc.2010.1168_bib0250","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beha.2008.08.004","article-title":"Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?","volume":"21","author":"Douer","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0255","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcome for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0260","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0265","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukaemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"De Bont","year":"2004","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1168_bib0270","first-page":"1551","article-title":"Swedish Adult Acute Lymphocytic Leukemia Group","volume":"107","author":"Hallbook","year":"2006","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0280","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3324\/haematol.12466","article-title":"Acute lymphoblastic leukemia in adolescents and young adults in Finland","volume":"93","author":"Usvasalo","year":"2008","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2010.1168_bib0285","first-page":"526a","article-title":"A multicenter phase II study using a dose intensified pediatric regiman in adults with untreated acute lymphoblastic leukaemia","volume":"108","author":"De Angelo","year":"2006","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0290","doi-asserted-by":"crossref","first-page":"531a","DOI":"10.1182\/blood.V108.11.1875.1875","article-title":"Treatment of adult acute lymphoblastic leukaemia (ALL) with a modified DFCI pediatric regimen. The Princess Margaret experience","volume":"108","author":"Storring","year":"2006","journal-title":"Blood"},{"issue":"S1","key":"10.1684\/bdc.2010.1168_bib0295","first-page":"366","article-title":"Treatment of adults with newly diagnosed acute lymphoblastic leukemia with multiple doses of intravenous pegylated asparaginase in an intensified pediatric regimen","volume":"93","author":"Srivastava","year":"2008","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2010.1168_bib0300","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1749-6632.1971.tb31156.x","article-title":"L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y","volume":"186","author":"Capizzi","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"10.1684\/bdc.2010.1168_bib0305","first-page":"1313","article-title":"L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y","volume":"47","author":"Sur","year":"1987","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1168_bib0310","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/1097-0142(197903)43:3<1089::AID-CNCR2820430346>3.0.CO;2-H","article-title":"Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood","volume":"43","author":"Lobel","year":"1979","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0315","first-page":"939","article-title":"Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia","volume":"64","author":"Amadori","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"10.1684\/bdc.2010.1168_bib0320","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(68)90977-X","article-title":"A new L-asparaginase with anti-tumor activity","volume":"2","author":"Wade","year":"1968","journal-title":"Lancet"},{"key":"10.1684\/bdc.2010.1168_bib0325","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/mpo.10096","article-title":"Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase","volume":"38","author":"Albertsen","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0330","first-page":"669a","article-title":"The importance of L-asparaginase in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli (E. coli) as compared to Erwinia","volume":"88","author":"Otten","year":"1996","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0335","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1684\/bdc.2010.1168_bib0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14712590802586058","article-title":"Pegasparaginase: where do we stand?","volume":"9","author":"Zeidan","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1684\/bdc.2010.1168_bib0345","first-page":"628a","article-title":"Randomized trial of PEG vs native asparaginase in children with newly diagnosed acute lymphoblastic leukemia (ALL): CCG study 1962","volume":"94","author":"Holcenberg","year":"1999","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0350","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1168_bib0355","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against polyethylene glycol adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0360","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2002-04-1282","article-title":"Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL)","volume":"100","author":"Pinheiro","year":"2002","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0365","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2141.2004.04863.x","article-title":"The best way to use asparaginase in childhood acute lymphatic leukaemia \u2013 still to be defined?","volume":"125","author":"Pinheiro","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0370","first-page":"24","article-title":"A pharmaceutical study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia","volume":"91","author":"Rizzari","year":"2006","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2010.1168_bib0375","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1158\/1078-0432.CCR-04-0222","article-title":"Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia","volume":"10","author":"Hawkins","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2010.1168_bib0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-872516","article-title":"Asparagine concentration in plasma after 2,500 IU\/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia","volume":"217","author":"Wenner","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1684\/bdc.2010.1168_bib0385","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1168_bib0390","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V112.11.302.302","article-title":"PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): Efficacy and feasibility analysis with increasing dose levels","volume":"112","author":"Goekbuget","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0400","first-page":"672","article-title":"Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase","volume":"112","author":"Rytting","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0405","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0410","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3","article-title":"Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia","volume":"86","author":"Aguayo","year":"1999","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0415","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1168_bib0420","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2141.2003.04707.x","article-title":"Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study","volume":"123","author":"Rosen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0425","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1684\/bdc.2010.1168_bib0430","first-page":"803","article-title":"Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant Erwinia chrysantemi-derived L-asparaginase","volume":"114","author":"Allas","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0435","first-page":"803","article-title":"Immunogenicity profile in mice of a pegylated recombinant Erwinia chrysantemi-derived L-asparaginase","volume":"114","author":"Allas","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1168_bib0440","first-page":"1733","article-title":"Permeability of human erythrocytes to asparagine","volume":"50","author":"Ataullakhanov","year":"1985","journal-title":"Biokhimiia"},{"key":"10.1684\/bdc.2010.1168_bib0445","first-page":"679","article-title":"Infusion of red blood cell-loaded asparaginase in monkey","volume":"101","author":"Updike","year":"1983","journal-title":"J Lab Clin Med"},{"key":"10.1684\/bdc.2010.1168_bib0450","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.2042-7158.1990.tb06598.x","article-title":"Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies","volume":"42","author":"Kravtzoff","year":"1990","journal-title":"J Pharm Pharmacol"},{"key":"10.1684\/bdc.2010.1168_bib0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0006-2952(85)90133-9","article-title":"Therapeutic efficacy of asparaginase encapsulated in intact \u00e9rythrocytes","volume":"34","author":"Alpar","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1684\/bdc.2010.1168_bib0460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1470-8744.1988.tb00026.x","article-title":"Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes","volume":"10","author":"Naqi","year":"1988","journal-title":"Biotechnol appl Biochem"},{"key":"10.1684\/bdc.2010.1168_bib0465","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00195932","article-title":"Improved pharmacodynamics of L-asparaginase loaded in red blood cells","volume":"49","author":"Kravtzoff","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl.1","key":"10.1684\/bdc.2010.1168_bib0470","first-page":"119","article-title":"GRASPALL 2005-01 clinical study: L-asparaginase loaded into red blood cells is effective at depleting serum asparagine in children and adults with relapsed acute lymphoblastic leukemia (ALL)","volume":"112","author":"Bertrand","year":"2008","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T19:57:55Z","timestamp":1721591875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115307864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":94,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0007455115307864"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2010.1168","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2015\/627031","asserted-by":"object"}]},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}